How can alpha thalassemia be confirmed in a neonate?

Confirming Alpha Thalassemia in a Neonate

Alpha thalassemia in neonates is confirmed by detecting Hemoglobin Bart's (γ4) on hemoglobin analysis of cord blood or neonatal blood samples, followed by DNA testing to identify specific α-globin gene deletions or mutations.

Diagnostic Approach

Initial Screening: Hemoglobin Bart's Detection

• Hemoglobin Bart's is the diagnostic hallmark of α-thalassemia in the neonatal period, as it is only present until approximately 6 months of age 1, 2.
• The level of Hb Bart's correlates directly with the degree of α-gene deletion: higher percentages indicate more severe forms 2, 3.
• Hb Bart's levels interpretation:
  • 0-0.1%: Normal (αα/αα genotype) 3
  • 0.1-2%: Silent carrier (--α/αα genotype) - though trace amounts may not always be detected 3

  • 2%: α-thalassemia trait (--α/--α genotype) 3

  • 5-30%: Hemoglobin H disease 1

  • 80%: Alpha thalassemia major (homozygous α0-thalassemia) 4

Testing Methods

Hemoglobin Analysis:

• Capillary electrophoresis (CE) using either fresh cord blood or dried blood spot (DBS) specimens is highly effective 1.
• The Capillarys Cord Blood programme shows 91.7% sensitivity and 100% specificity 1.
• Isoelectric focusing (IEF) on dried blood spots is an alternative method with 92.86% sensitivity and 74% specificity when using a cut-off of ≥0.25% Hb Bart's 5.
• High-performance liquid chromatography (HPLC) can also detect Hb Bart's 1.

Red Cell Indices as Screening Tool:

• Mean corpuscular volume (MCV) <93.5 fL in cord blood suggests the need for hemoglobin electrophoresis to identify two- or three-gene deletion α-thalassemia 2.
• However, red cell indices alone cannot reliably identify single-gene deletion (silent carrier) α-thalassemia 2.
• Parental screening showing MCV <80 fL suggests thalassemia carrier status and should prompt neonatal evaluation 6.

Confirmatory Testing: DNA Analysis

Molecular diagnosis is essential for definitive confirmation and provides critical information for genetic counseling 6, 1.

• DNA testing methods include:

  • Multiplex ARMS Gap-PCR (amplification refractory mutation system) 1
  • Next-generation sequencing combined with Gap-PCR (NGS-Gap-PCR) - superior to traditional methods, detecting additional cases missed by conventional testing 7
  • Restriction fragment length polymorphism (RFLP) 6
  • Accurate circular consensus long-read sequencing for rare variants 8

• Common α-thalassemia genotypes identified:

  • αα/--SEA (Southeast Asian deletion) - most common 1
  • -α3.7/-α3.7 (homozygous α+ deletion) 1
  • αα/-α3.7 (heterozygous α+ deletion) 1
  • αα/ααCS (Constant Spring variant) 1

Clinical Context

When to suspect α-thalassemia in neonates:

• Nonimmune hydrops fetalis (NIHF), particularly in Southeast Asian populations where α-thalassemia accounts for 28-55% of NIHF cases 6.
• Severe fetal anemia detected on middle cerebral artery Doppler (peak systolic velocity >1.5 multiples of the median) 6.
• Family history or parental carrier status 6.

Important Caveats

• Timing is critical: Hb Bart's disappears by 6 months of age, making early neonatal testing essential 2.
• False negatives occur: Hemoglobin analysis may miss silent carriers (single α-gene deletion) 2, 3.
• Prenatal diagnosis can be made by detecting common DNA deletions/mutations in amniotic fluid or fetal blood, or by identifying abnormal Bart's hemoglobin in fetal blood samples 6.
• In regions with high α-thalassemia prevalence (>10% carrier rate), universal neonatal screening is cost-effective for genetic counseling and prevention 7, 5.